Encouraging results have been reported for a new drug for the treatment of age-related macular degeneration. Dr. Skouteris is taking part in this study, which is being conducted at dozens of centres across Europe, as a sub-investigator through Oxford University Hospital. The aim of this new drug is to be given every three months, thereby reducing the burden of monthly injections. Many research groups share this approach, since it will lower costs but, above all, it will reduce the volume of patients that hospitals have to manage, which is becoming increasingly unsustainable worldwide.
The patient will benefit just as much: instead of having one injection every month, with the new drugs they may not need another injection for two, three or even more months.
Dr Skouteris is also taking part in a second study aiming at the same desired outcome, which is being carried out by a different research group.
Questions about your case?
Dr. Skouteris will examine you at his practice in Neo Psychiko and explain your options.
Ophthalmic surgeon trained at the John Radcliffe University Hospital in Oxford and Fellow of the European Board of Ophthalmology (FEBO).
Full profileRelated articles
Diabetic Maculopathy (Diabetic Macular Oedema)
Diabetic macular oedema is one of the conditions that affect the macula, a term many people have heard of nowadays because of…
Read the article
Aftercare Instructions after an Intravitreal Injection
Please follow the aftercare instructions below after your intravitreal injection to avoid a possible infection or other serious complication from the injection:…
Read the article
Protecting Your Eyes in Summer: The 3 Most Common Mistakes
Proper summer eye protection from solar radiation is extremely important. It is widely known how beneficial the sun can be for our…
Read the article